Carbonic Anhydrase I as a New Plasma Biomarker for Prostate Cancer

Serum prostate-specific antigen (PSA) levels ranging from 4 to 10 ng/mL is considered a diagnostic gray zone for detecting prostate cancer because biopsies reveal no evidence of cancer in 75% of these subjects. Our goal was to discover a new highly specific biomarker for prostate cancer by analyzing plasma proteins using a proteomic technique. Enriched plasma proteins from 25 prostate cancer patients and 15 healthy controls were analyzed using a label-free quantitative shotgun proteomics platform called 2DICAL (2-dimensional image converted analysis of liquid chromatography and mass spectrometry) and candidate biomarkers were searched. Among the 40,678 identified mass spectrum (MS) peaks, 117 peaks significantly differed between prostate cancer patients and healthy controls. Ten peaks matched carbonic anhydrase I (CAI) by tandem MS. Independent immunological assays revealed that plasma CAI levels in 54 prostate cancer patients were significantly higher than those in 60 healthy controls (P = 0.022, Mann-Whitney U test). In the PSA gray-zone group, the discrimination rate of prostate cancer patients increased by considering plasma CAI levels. CAI can potentially serve as a valuable plasma biomarker and the combination of PSA and CAI may have great advantages for diagnosing prostate cancer in patients with gray-zone PSA level.

[1]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[2]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[3]  J. Pannek,et al.  Prostate-specific antigen: what's new in 1997. , 1997, Oncology.

[4]  Y. Kanai,et al.  Use of quantitative shotgun proteomics to identify fibronectin 1 as a potential plasma biomarker for clear cell carcinoma of the kidney. , 2012, Cancer biomarkers : section A of Disease markers.

[5]  J. Cervera Deval,et al.  [Diagnostic value of the second prostate biopsies in males of risk. Study stratified by value of PSA]. , 2004, Actas urologicas espanolas.

[6]  W. Catalona,et al.  The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. , 1999, Clinical chemistry.

[7]  C. Supuran.  Carbonic anhydrase inhibition/activation: trip of a scientist around the world in the search of novel chemotypes and drug targets. , 2010, Current pharmaceutical design.

[8]  Tesshi Yamada,et al.  Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex. , 2005, Gastroenterology.

[9]  N. Sata,et al.  Prolyl 4-hydroxylation of alpha-fibrinogen: a novel protein modification revealed by plasma proteomics. , 2009, The Journal of biological chemistry.

[10]  N. Sata,et al.  Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray , 2011, Cancer science.

[11]  Igor Sartori,et al.  Detection of Organ-Confined Prostate Cancer Is Increased Through Prostate- Specific Antigen-Based Screening: , 1994 .

[12]  J. C. Deval,et al.  Valor diagnóstico de segundas biopsias prostáticas en varones de riesgo: Estudio estratificado por valor de PSA , 2004 .

[13]  Setsuo Hirohashi,et al.  Label-free Quantitative Proteomics Using Large Peptide Data Sets Generated by Nanoflow Liquid Chromatography and Mass Spectrometry* , 2006, Molecular & Cellular Proteomics.

[14]  D. Ornstein,et al.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. , 1997, JAMA.

[15]  William J Catalona,et al.  What to do with an abnormal PSA test. , 2008, The oncologist.

[16]  Hisashi Hirano,et al.  A novel approach and protocol for discovering extremely low‐abundance proteins in serum , 2006, Proteomics.

[17]  N. Sata,et al.  Reduced Plasma Level of CXC Chemokine Ligand 7 in Patients with Pancreatic Cancer , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[18]  J. Dekker,et al.  Epithelial proliferation, cell death, and gene expression in experimental colitis: alterations in carbonic anhydrase I, mucin MUC2, and trefoil factor 3 expression , 2002, International Journal of Colorectal Disease.

[19]  E. Swenson.  Distribution and Functions of Carbonic Anhydrase in the Gastrointestinal Tract , 1991 .

[20]  W. Catalona,et al.  Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA). , 2009, Urologic oncology.

[21]  Andrew J. Vickers,et al.  Prostate-specific antigen and prostate cancer: prediction, detection and monitoring , 2008, Nature Reviews Cancer.

[22]  Louis R Kavoussi,et al.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. , 1994, The Journal of urology.

[23]  S. Hirohashi,et al.  Poly(ADP-Ribose) Polymerase-1 Is a Component of the Oncogenic T-Cell Factor-4/β-Catenin Complex , 2005 .

[24]  S. Hirohashi,et al.  Large‐scale quantitative clinical proteomics by label‐free liquid chromatography and mass spectrometry , 2009, Cancer science.

[25]  Andrea Scozzafava,et al.  Carbonic anhydrases as targets for medicinal chemistry. , 2007, Bioorganic & medicinal chemistry.

[26]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[27]  M. Ono,et al.  Biomarker Discovery of Pancreatic and Gastrointestinal Cancer by 2DICAL: 2-Dimensional Image-Converted Analysis of Liquid Chromatography and Mass Spectrometry , 2012, International journal of proteomics.

[28]  G. Lönnerholm,et al.  Carbonic anhydrase in the human fetal gastrointestinal tract. , 1983, Biology of the neonate.